Capital Raising

Neopharma Technologies Ltd

The Worlds Leading Drugs of Abuse and Health Data Solution

I am interested

The Worlds Leading Drugs of Abuse and Health Data Solution

I am interested

x

INDUSTRY

Medical

RAISING

A$2M

PRE-MONEY VALUATION

A$20M

OFFER PRICE

A$0.30

Investment Highlights Company Overview Products & Services Transaction Overview Additional Information Team

Transaction Summary

Neopharma Technologies Ltd

  • Raising A$2M

  • Pre IPO Opportunity

I am interested

Investment Highlights


  • Emerging global leader in the growing US$33B Medical Device and Technology, Rapid Test Market

  • Neopharma Technologies is recognised as a Top 100 Medical Device and Technology company globally

  • TamperLoks DataVault is a globally patented Drugs of Abuse testing solution

  • US FDA Regulatory pathway breakthrough with US market access for TamperLoks anticipated Q1 2023.

Company Overview


  • Extensive Intellectual Property

    Portfolio of patents and trademarks patents for an extensive range of medical devices

  • myNEO

    World’s first Covid-19 testing app, integrated for all TGA and US FDA approved rapid antigen test kits

  • NEOVAULT

    ERM technology platform providing an accurate, safe and secure way to manage health testing programs.

Leader in medical device technology

Neopharma’s goal is to be a recognized global leader in the growing US$33B Medical Device and Technology, Rapid Test Market and $2.9B Track-and-Trace market.

Neopharma has produced a range of innovative rapid tests for Drugs-of-Abuse with its global patented TamperLoks and next-generation Saliva Drug Test NEOSWAB+ and Saliva Drug and Alcohol Test NEOSWAB DA+.

Also under development is a range of other rapid tests covering infectious disease, pregnancy and Covid-19/Flu.

The company has a US FDA Regulatory pathway for TamperLoks, anticipated in Q1 2023, and has secured Letters of Authorisation with leading Medical device manufacturers globally, with a number of KPI driven distribution agreements.

High-growth industry sector

Neopharma Technologies Ltd is an Australian public company in the US$33B Rapid Test Market and high growth Market.

Neopharma’s market-leading, patented TamperLoks medical device and next-generation Saliva Drug Test NEOSWAB+ and Saliva Drug and Alcohol Test NEOSWAB DA+, have significant market potential, along with its other range of products.

slide-image

Extensive IP & patents

Neopharma Technologies has an extensive intellectual property portfolio having secured patents and trademarks for its range of medical devices and supporting technologies.

The company is launching its Drug testing and rapid testing products globally in 2023 with its focus on the USA and AUS markets.

Products & Services


slide-image
slide-image
product-img

NEOTEST & myNEO: the World’s first Covid-19 testing app

Designed by Neopharma Technologies used with all US FDA and TGA-approved Covid-19 antigen and combined Covid-19 antigen & Flu AB test kits for the US and Australian markets.

product-img

Drugs-Of-Abuse Testing – Tamperloks Datavault

TamperLoks enables a rapid drugs-of-abuse urine test and assigns a unique QR code to the candidate being tested.

TamperLoks DataVault is a global leader in drugs-of-abuse testing. There is no current comparable hardware and technology pairing in the market globally.

product-img

Tamperloks – Rapid Drug Test Device

Patented 3-chamber tamperproof drugs-of-abuse urine testing device.

Test results within 90 seconds.

Patents ensure asset protection with further expansion into new markets.

Transaction Overview


Pre-IPO offer at 30 cents per share with a 1 for 1 free attaching option, exercisable at 30 cents with 2 years expiry.

Targeting an ASX listing in Q2 2023.

image

Additional Information


  • Other Documents

Team


  • Management
  • Directors
  • Gajenddra Raj

    Chief Technical Officer

    iconicon
  • Nikhil Kothari

    General Manager

    iconicon
  • Jason Yeun

    Chief Manaufacturing Engineer

    iconicon
  • Marcus L’Estrange

    Executive Chairman

    iconicon
  • Shaun Melville

    Executive Director

    iconicon
  • Neel Le Roux

    Non-Executive

    iconicon
  • Non-Executive

Want to learn more?

Fill in the expression of interest form below

    Thank you for your enquiry.
    We will be in touch as soon as possible.

    Speak to our investment team today

    +61 2 9993 4475